Clinical trial
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma…
NCT00335348 · Peter MacCallum Cancer Centre, Australia, Other · Completed
Key facts
| NCT number | NCT00335348 |
|---|---|
| Title | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse |
| Official title | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse An Australian Myeloma Forum Multi-Centre Phase II Trial |
| Lead sponsor | Peter MacCallum Cancer Centre, Australia, Other |
| Collaborators | Janssen-Cilag Ltd. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib, Dexamethasone |
| Enrollment | 101 |
| Start date | Jun 1, 2006 |
| Primary completion | Jul 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | Jun 9, 2006 |
| Last update posted | Jan 9, 2013 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: